PATRICK J ZENNER
CIK 1139036 · Exec. Chairman & Interim CEO · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$13.77M
Companies
10
Total Filings
105
Lifetime Open-Market Net
-$2.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNAC | Director | 12,974 | $9.30 | $120.7K | $0 | 4 | 2026-01-06 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 55,248 | $0.88 | $48.7K | $0 | 8 | 2023-01-04 |
| WST | Director | 39,974 | $338.65 | $13.54M | -$2.16M | 33 | 2022-04-01 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | Director | — | — | — | $0 | 4 | 2012-01-09 |
| GERN | Director | 73,710 | $1.48 | $109.1K | $0 | 6 | 2010-05-21 |
| EXACT SCIENCES CORP (EXAS) Delisted | Exec. Chairman & Interim CEO | 124,994 | $104.91 | $13.11M | $0 | 5 | 2009-07-21 |
| CURAGEN CORP (CRGN) Delisted | Director | 10,000 | — | — | $27.5K | 5 | 2009-02-13 |
| SCIELE PHARMA, INC. (SCRX) Delisted | Director | 43,705 | — | — | $49.9K | 3 | 2008-04-28 |
| PRCS | Director | — | $28.95 | — | $0 | 1 | 2007-02-08 |
| DENDRITE INTERNATIONAL INC (DRTE) Delisted | Director | 19,000 | — | — | $0 | 1 | 2007-01-29 |
Recent Filings · Page 6 of 11
105 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-10-02 | — | Disp (D) | — | $0 | |
| 2012-07-12 | WST | Exer (M) | +1,500 | $19.3K | EDGAR |
| 2012-06-14 | — | Buy (P) | +4,000 | $25.9K | |
| 2012-05-29 | — | Grant (A) | — | $0 | |
| 2012-05-03 | WST | Grant (A) | +2,459 | $0 | EDGAR |
| 2012-01-09 | PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-12-05 | — | Buy (P) | +4,400 | $24.3K | |
| 2011-06-02 | — | Grant (A) | — | $0 | |
| 2011-05-19 | PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-05-05 | WST | Grant (A) | +2,325 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.